M&T Bank Corp increased its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 25.1% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,324 shares of the medical research company’s stock after buying an additional 467 shares during the period. M&T Bank Corp’s holdings in Bio-Rad Laboratories were worth $525,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Canada Pension Plan Investment Board bought a new position in Bio-Rad Laboratories in the second quarter worth approximately $113,000. Pacad Investment Ltd. bought a new position in Bio-Rad Laboratories in the second quarter worth approximately $113,000. Turner Investments LLC bought a new position in Bio-Rad Laboratories in the second quarter worth approximately $136,000. Capital Analysts LLC bought a new position in Bio-Rad Laboratories in the second quarter worth approximately $170,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Bio-Rad Laboratories by 12.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 815 shares of the medical research company’s stock worth $184,000 after buying an additional 90 shares in the last quarter. 62.84% of the stock is owned by institutional investors.

A number of brokerages recently commented on BIO. Zacks Investment Research raised shares of Bio-Rad Laboratories from a “sell” rating to a “hold” rating in a research note on Wednesday. Deutsche Bank AG reissued a “buy” rating and issued a $255.00 price objective on shares of Bio-Rad Laboratories in a research note on Monday, September 18th. TheStreet downgraded shares of Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research note on Thursday, August 3rd. Jefferies Group LLC reissued a “buy” rating and issued a $275.00 price objective on shares of Bio-Rad Laboratories in a research note on Friday, July 14th. Finally, Wells Fargo & Company began coverage on shares of Bio-Rad Laboratories in a research note on Thursday, July 13th. They issued an “outperform” rating and a $250.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Bio-Rad Laboratories has a consensus rating of “Buy” and a consensus price target of $240.00.

Bio-Rad Laboratories, Inc. (NYSE BIO) opened at 226.26 on Friday. The stock’s 50 day moving average price is $221.47 and its 200-day moving average price is $220.14. The firm has a market capitalization of $6.71 billion, a P/E ratio of 447.15 and a beta of 0.91. Bio-Rad Laboratories, Inc. has a 12 month low of $154.89 and a 12 month high of $242.79.

ILLEGAL ACTIVITY NOTICE: “M&T Bank Corp Acquires 467 Shares of Bio-Rad Laboratories, Inc. (BIO)” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/mt-bank-corp-acquires-467-shares-of-bio-rad-laboratories-inc-bio/1614761.html.

In other news, EVP Michael Crowley sold 700 shares of the firm’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $215.91, for a total value of $151,137.00. Following the sale, the executive vice president now directly owns 2,060 shares in the company, valued at approximately $444,774.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 28.29% of the stock is currently owned by company insiders.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.